Arylacenamide (SR31747) is a peripheral [sigma] ligand that binds four proteins in human cells, i.e. SRBP-1, [sigma]-2, HSI and its relative SRBP-2. It is a dual agent with both immunomodulatory...
- Mechanism
- Curator reviewed
SR31747 blocks proliferation of human lymphocytes, modulates the expression of pro- and anti-inflammatory cytokines, and was shown to protect animals in vivo against acute and chronic inflammatory conditions such as acute graft-versus-host reaction, lethality induced by staphylococcal enterotoxin B and lipopolysaccharide or rheumatoid arthritis. Besides these immunomodulatory activities, the molecule also inhibits the proliferation of various tumor cell lines in vitro in a time- and concentration-dependent manner.
- Primary indication
- Investigated for use/treatment in cancer/tumors (unspecified), immunosuppressive, and prostate cancer.Curator reviewed
- Formula / weight
- C23H35Cl2N · 396.437 g/mol (avg)
- Code names
- SR-31747
Resolves to
HKHPCMBPASXYGP-KVVVOXFISA-NSMILESCl.CCN(C\C=C/C1=CC(Cl)=C(C=C1)C1CCCCC1)C1CCCCC1What you can answer from here — as of March 06, 2025
Which drugs share a target with Arylacenamide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account